Periodic Reporting for period 1 - SUPAIR Spectroscopy (Single-Use unit and Process Analytical Infrared Spectroscopy)
Reporting period: 2020-05-01 to 2021-01-31
IRUBIS GmbH develops a novel robust sensor system that enables continuous monitoring of bioreactors using mid-infrared spectroscopy and single use flow-cells for the manufacturing of biological drugs, such as vaccines. The EU-funded SUPAIR Spectroscopy project aims to conclude technological developments and lay the groundwork for successful market commercialisation. The objective of the SUPAIR Spectroscopy project is to optimize the technical developments of the mid-infrared spectroscopy system and optimize the instrument to the customer needs. Especially the validation of the monitoring solution by biopharma companies is essential.
Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far
During the first 9 month of the action the hardware and software were optimised to the need of biopharma companies. Currently, if in the bioprocess different cell lines and cell media are used, a new calibration model for the spectroscopic system is obligatory. IRUBIS developed a new approach in order to reduce the effort for calibration model building significantly. The system was tested during the first period of the project at biopharma companies and academia.
Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)
The potential impact of the instrument is on the one hand to increase the product gain and quality of biopharmaceutical drugs by a continuous control of the nutrient parameter in the bioprocess. This leads to a higher process know-how and decrease the time for process development. In a consequence the new technology brings biopharmaceuticals faster to the patient.